Want to join the conversation?
$AGN said FDA approved its supplemental New Drug Application (sNDA) to update label for AVYCAZ (ceftazidime and avibactam) with clinical data from Phase 3 trial evaluating safety and efficacy of AVYCAZ, in combination with metronidazole, for treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.